ArticleTranslational cancer research2026
A P-body-related risk score predicts prognosis and immune microenvironment in lung adenocarcinoma.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Processing bodies (P-bodies) are cytoplasmic granules involved in post-transcriptional gene regulation and play pivotal roles in carcinogenesis. However, the clinical significance of P-body-associated genes in lung adenocarcinoma (LUAD) remains poorly understood. This study aimed to investigate the clinical prognostic significance and potential biological roles of P-body-associated genes in LUAD, and establish a gene-based prognostic model for clinical application. Methods: Twenty-four core P-body-related genes were curated from a user-friendly database RNAgranuleDB. Using transcriptomic and clinical data from The Cancer Genome Atlas (TCGA) LUAD cohort, univariate Cox regression was performed to screen prognostic genes, followed by least absolute shrinkage and selection operator (LASSO)-Cox regression with ten-fold cross-validation to construct a P-body-related risk score based on five retained genes ( Results: The P-body-related risk score served as an independent prognostic factor in LUAD, with high score significantly associated with worse overall survival (OS), progression-free interval (PFI), and disease-specific survival (DSS) in the TCGA cohort. These findings were consistently validated across five independent GEO cohorts. Functionally, high scores were associated with enhanced mRNA editing, activation of cell cycle pathways (G2/M checkpoint, E2F targets), PI3K-AKT-mTOR signaling, and DNA repair activity, as well as increased genomic instability markers including tumor mutational burden (TMB), tumor neoantigen burden (TNB), and homologous recombination deficiency (HRD). Regarding the tumor immune microenvironment, low score correlated with an immunologically active phenotype characterized by increased infiltration of CD8 Conclusions: We developed and validated a P-body-related five-gene risk score that independently predicts LUAD prognosis and stratifies immune phenotypes. As these genes have extra-P-body functions, the score serves as a transcriptomic proxy for P-body component enrichment, not a direct measure of P-body activity. Despite this limitation, it offers a clinically useful tool for risk stratification and mechanistic hypotheses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.